Healthcare Professionals > Oncotype DX Breast Recurrence Score

Clinical evidence for the Oncotype DX® test in node-positive patients

The Recurrence Score® result has been proven to be predictive of chemotherapy benefit for HR+, HER2-, node-positive postmenopausal patients in the retrospective SWOG-8814 study.1 The prospective randomised trial RxPONDER including more than 5,000 patients was designed to refine chemotherapy benefit estimates for HR+, HER2- patients with Recurrence Score results 0-25 and 1 to 3 positive nodes.3 Initial results of the RxPONDER study have been described as practice-changing.3-5

  • The majority of N1 postmenopausal patients may be spared chemotherapy based on Recurrence Score® results 0-25, independent of clinical pathological parameters3-5
  • N1 premenopausal patients with Recurrence Score results 0-25 have a modest 2.4% benefit from chemotherapy in terms of distant recurrence-free interval at 5 years4

Clinical Evidence


The Oncotype DX Breast Recurrence Score test identifies the vast majority of women who may not receive a benefit from chemotherapy and can ultimately be spared chemotherapy.1

  • Oncotype DX is the only test that has been clinically validated to predict chemotherapy benefit and that can thus be used to distinguish patients who will benefit from chemotherapy from those who may be spared chemotherapy.1,6-7 Find out more about the difference between prognostic and predictive tests
  • The Oncotype DX test has been studied in over 96,000 breast cancer patients in over 79 clinical and registry studies.1-14
  • There is a consistent and large body of evidence across randomised, prospective and retrospective studies and real-world evidence.1-14
  • The Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended as the “preferred” test by NCCN®. In addition, it is recommended by two major European health technology assessment bodies.15-20

Contact Us